PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.32%
Both companies show declining cash positions (-7.32% vs AVXL's -4.73%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.32%
Cash + STI yoy ≥ 1.5x AVXL's -4.73%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.49%
Above 1.5x AVXL's -12.09%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-6.31%
1.25-1.5x AVXL's -4.22%. Bruce Berkowitz checks if strong current asset growth is used effectively.
-8.93%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.62%
Less than half of AVXL's 100.00%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-7.75%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
≥ 1.5x AVXL's -4.22%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.18%
Less than half of AVXL's 48.25%. David Dodd sees fewer expansions in other current obligations.
5.07%
Less than half of AVXL's 30.20%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.44%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
0.54%
Less than half of AVXL's 30.20%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.80%
0.5-0.75x AVXL's -3.58%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.26%
≥ 1.5x AVXL's -7.33%. David Dodd sees stronger capital base growth than competitor.
-6.35%
≥ 1.5x AVXL's -4.22%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.07%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
7.30%
Above 1.5x AVXL's 4.73%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.